Medicus Pharma Ltd. (NASDAQ: MDCX) filed an Orphan Drug Designation (ODD) application with the U.S. Food and Drug Administration for its SkinJect therapy, a dissolvable microneedle array that delivers doxorubicin directly to skin lesions. The application targets basal cell carcinoma (BCC) in patients with Gorlin syndrome, a rare genetic disorder that predisposes individuals to multiple, recurrent skin cancers.
SkinJect has progressed through Phase 1 and Phase 2 studies, showing a favorable safety profile and an 80 % overall response rate in the 200 µg cohort reported in March 2026. The microneedle platform offers a localized, non‑surgical treatment that could reduce the need for repeated surgical excisions, a common burden for Gorlin syndrome patients.
An ODD award would grant SkinJect seven years of U.S. market exclusivity upon approval, along with tax credits, fee waivers and enhanced regulatory support. These incentives are designed to accelerate development and commercialization for rare disease indications, making the designation a strategic milestone for Medicus Pharma’s pipeline.
There are currently no FDA‑approved therapies specifically for BCC in Gorlin syndrome. Existing options include surgical removal, radiation therapy and hedgehog‑pathway inhibitors such as vismodegib. SkinJect’s localized, non‑surgical approach could differentiate it from these modalities and address a significant unmet need in a patient population of roughly 11,000 in the United States.
Medicus Pharma’s market capitalization is modest and the company has limited cash resources, with approximately $2.5 million remaining under a standby equity purchase agreement as of March 2026. The ODD filing therefore represents a critical step that could enhance the company’s ability to secure additional funding and advance its development program. Executive Chairman and CEO Dr. Raza Bokhari has emphasized the potential impact of SkinJect for patients with Gorlin syndrome, underscoring the company’s focus on precision medicine and AI‑enabled clinical development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.